Array acquires BRAF inhibitor from Novartis

Array BioPharma Inc. (NASDAQ:ARRY) surged $2.06 (41%) to $7.11 after gaining worldwide rights to encorafenib ( LGX818) from Novartis AG (NYSE:NVS; SIX:NOVN). Array said it will make a "de

Read the full 298 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE